The pneumolysin toxoid, Δ6 PLY, is a prototype pneumococcal protein vaccine candidate. However, its potentially detrimental residual proinflammatory interactions with human neutrophils are unknown. In the current study the effects of the toxoid (8-1000 ng/ml) have been compared with those of wild-type pneumolysin (WT/PLY, 8 ng/ml) on neutrophil cytosolic Ca 2+ fluxes, generation of leukotriene B 4 (LTB 4 ), and release of matrix metalloproteinase-9 (MMP-9), using spectrofluorimetric, and ELISA procedures (LTB 4 and MMP-9) respectively. Exposure of neutrophils to WT/PLY resulted in influx of Ca 2+ and significant (P<0.05) release of MMP-9
Introduction
Although they induce capsular polysaccharide-targeted antibody responses which effectively reduce colonization and disease, the restricted number of serotypes and absence of pneumococcal protein antigens represent potential limitations of current pneumococcal conjugate vaccines. Both limitations may be overcome, however, by the development of vaccines based on highlyconserved, broadly serotype-unrestricted, recombinant, surface and subsurface pneumococcal protein antigens. [1] [2] [3] [4] Prominent among the protein antigen vaccine candidates are pneumococcal surface adhesin A (PsaA), and surface proteins A (PspA) and C (PspC, also known as choline-binding protein A), as well as the cholesterol-binding, pore-forming toxin, pneumolysin (PLY). PLY, for the following reasons, is generally considered to be a particularly attractive protein vaccine candidate: i) it is produced by almost all clinical isolates of the pneumococcus; 5 ii) it is generally considered to be the most potent protein virulence factor of the pneumococcus; 5, 6 iii) administration of recombinant PLY into the apical lobe bronchus of rats results in a severe lobar pneumonia with histologic features typical of pneumococcal pneumonia; 7 and iv) the toxin has already been validated as a candidate vaccine antigen. 8, 9 However, because of its cytotoxic effects on eukaryotic cells, the development of PLY-based vaccines necessitates the generation of recombinant variants of the toxin which are attenuated with respect to pore-forming activity in the setting of retention of immunogenicity. One of the most promising of these is Δ6 PLY, generated by site-directed mutagenesis (deletion of alanine 146 and arginine 147 in the pore-forming region of wild-type PLY). 10 Critical criteria for further development include immunological and histological evaluation of protective efficacy and safety in animal models, as well as in vitro determination of attenuation of pore-forming activity in haemolytic assays.
This latter assessment, although well-accepted, does not, however, detect the sub-lytic activity which underpins the potentially harmful pro-inflammatory activity of the toxin with other cell-types such as neutrophils 11 and epithelial cells. 12 In the current study, we have therefore compared the effects of WT/PLY and Δ6 PLY on several Ca
2+
-dependent pro-inflammatory activities of human neutrophils in vitro.
Materials and Methods
Unless indicated, all chemicals and reagents were obtained from the Sigma Chemical Co. (St Louis, MO, USA).
Wild-type pneumolysin and D6 PLY1
Recombinant WT/PLY was expressed in Escherichia coli and purified from cell extracts as described previously, 13 while Δ6 PLY, with a double amino acid deletion in the pore-forming region of the toxin (alanine 146 and arginine 147) was generated by site-directed mutagenesis and was also expressed in E. coli. 10 The purities of both toxins were confirmed by sodium dodecylsulphate-polyacrylamide gel electrophoresis. The stock protein concentrations of WT/PLY and Δ6 PLY were 493 and 768 mg/ml respectively and were essentially free of contaminating endotoxin (0.103 and 0.073 IU/mg).
The respective haemolytic activities (using human erythrocytes, 1% final)
were 22700 and 0 haemolytic units/pmol.
Neutrophilis
Permission to draw blood from healthy adult human volunteers was granted by the Faculty of Health Sciences Research Ethics Committee of the University of Pretoria, and prior informed consent was obtained from all participants.
Purified neutrophils were prepared from heparinized venous blood as described previously using barrier centrifugation, followed in succession by sedimentation of erythrocytes with 3% gelatin, and removal of residual erythrocytes by hypotonic lysis. 11 The neutrophils, which were routinely of high purity (>90%) and viability (>95%), were resuspended to 1x10 7 
Results

Cytosolic Ca 2+ fluxes
Traces from two typical experiments (n=4 in the series) are shown in Figure 1 .
Addition of WT/PLY (8 ng/ml) to neutrophils was followed in succession by a short lag phase (~20sec) and a steep increase in fluorescence intensity due to influx of extracellular Ca 2+ , 11 which rapidly reached a sustained plateau phase. Δ6 PLY, at concentrations of 8 and 40 ng/ml, did not promote Ca 2+ influx, while at 1000 ng/ml the mutant toxin caused a slight influx of Ca 2+ following a prolonged lag phase of several minutes.
MMP-9 and leukotriene B 4
These results are shown in Figure 2 . Addition of WT/PLY (8 ng/ml), but not Δ6 PLY (1000 ng/ml), caused significant release of MMP-9 from neutrophils and a striking increase in the generation of LTB 4 .
Discussion
Using human neutrophils as sensitive indicator cells, we have demonstrated that the pneumolysoid, Δ6 PLY, is devoid of detectable pro-inflammatory activity, an essential property of a PLY-based pneumococcal vaccine. 14 The proposed absence of pro-inflammatory activity is based on the observations that following its addition to neutrophils, Δ6 PLY, at concentrations as high as 1000 ng/ml caused only a modest Ca 2+ influx and failed to activate either the release of MMP-9 or the generation of LTB 4. Both of these are potent effectors of neutrophil-mediated inflammation and tissue damage. 15, 16 We cannot, however, exclude the possibility that at longer exposure times, in excess of 10 minutes, significant Ca 2+ influx and cytotoxicity may occur.
In contrast, treatment of neutrophils with an extremely low, sub-lytic concentration of PLY 11 caused significant release of MMP-9 and generation of LTB 4 as reported previously. 17, 18 These pro-inflammatory interactions of the toxin with neutrophils were associated with influx of Ca 2+ , 11 an event which precedes and is a pre-requisite for mobilization of secondary/tertiary granules 19 and eicosanoid production. 20 Although Δ6 PLY at 1000 ng/ml caused modest Ca 2+ influx following a protracted lag phase, the resultant increment in cytosolic Ca 2+ did not achieve the necessary threshold for either degranulation or production of LTB 4 .
Taken together with retention of immunogenicity and lack of toxicity in a murine model of pulmonary damage, 10 
